Disclosure Of Effect Of Changes In Foreign Exchange Rates [Text Block]

Innate Pharma - Filing #882171

Concept	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31
Disclosure of effect of changes in foreign exchange rates [text block]	—	—	—	—	—	—	—	—	—
Disclosure of information when currency is not exchangeable into another currency [text block]	—	—	—	—	—	—	—	—	—
Disclosure of information when foreign operation’s functional currency is not exchangeable into presentation currency [text block]	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [text block]	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [abstract]
Disclosure of summarised financial information about foreign operation [line items]
Non-current assets	129 241 EUR	—	—	—	—	133 972 EUR	—	—	—
Current assets	138 256 EUR	—	—	—	—	173 451 EUR	—	—	—
Non-current liabilities	80 169 EUR	—	—	—	—	105 959 EUR	—	—	—
Current liabilities	79 886 EUR	—	—	—	—	45 488 EUR	—	—	—
Revenue	—	—	—	24 703 EUR	—	—	69 773 EUR	—	—
Profit (loss) from continuing operations	—	—	—	45 478 EUR	—	—	829,000 EUR	—	—
Profit (loss) from discontinued operations	—	—	—	7 331 EUR	—	—	63 155 EUR	—	—
Profit (loss)	—	52 809 EUR	—	52 809 EUR	—	—	63 984 EUR	63 984 EUR	—
Other comprehensive income	—	—	—	101,000 EUR	—	—	22,000 EUR	—	—
Comprehensive income	—	52 809 EUR	101,000 EUR	52 708 EUR	805,000 EUR	—	63 962 EUR	63 984 EUR	827,000 EUR